Cargando…
Serial troponin measurements to monitor risk and response to endothelin A antagonism in chronic kidney disease
Autores principales: | Anand, Atul, Farrah, Tariq E, Miller-Hodges, Eve, Shah, Anoop S V, Strachan, Fiona E, Carter, Edwin, Johnston, Neil R, Webb, David J, Mills, Nicholas L, Dhaun, Neeraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834594/ https://www.ncbi.nlm.nih.gov/pubmed/32984897 http://dx.doi.org/10.1093/ndt/gfaa214 |
Ejemplares similares
-
Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
por: Farrah, Tariq E., et al.
Publicado: (2019) -
Use of High-Sensitivity Cardiac Troponin in Patients With Kidney Impairment: A Randomized Clinical Trial
por: Gallacher, Peter J., et al.
Publicado: (2021) -
High-Sensitivity Cardiac Troponin and the Risk Stratification of Patients With Renal Impairment Presenting With Suspected Acute Coronary Syndrome
por: Miller-Hodges, Eve, et al.
Publicado: (2018) -
Plasma Pro‐Endothelin‐1 Peptide Concentrations Rise in Chronic Kidney Disease and Following Selective Endothelin A Receptor Antagonism
por: Dhaun, Neeraj, et al.
Publicado: (2015) -
Effect of Exercise Intensity and Duration on Cardiac Troponin Release
por: Marshall, Lucy, et al.
Publicado: (2020)